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Abstract
Post-cardiac arrest syndrome (PCAS) incorporates post-cardiac arrest brain injury, post-
cardiac arrest myocardial dysfunction, systemic ischemia/reperfusion syndrome and 
the precipitating pathology. Brain injury remains the leading cause of death in the post-
cardiac arrest period. One of our main goals during post-resuscitation care is to guide a 
proper neuroprotective strategy. We are going to summarize the tools of neuroprotec-
tion in post-cardiac arrest therapy. The role of normoxia/normocapnia, normoglycemia, 
seizure control, sedation and pharmacologic strategies will be discussed in brief. The 
handling of temperature management and the management of hemodynamic variables 
to secure satisfactory cerebral perfusion will be worked out in details. Targeted tempera-
ture management is the main tool of neuroprotection in post-cardiac arrest therapy. We 
are going to conclude the principles of temperature control after successful resuscita-
tion pointing out its beneficial effects. This method has also several complications that 
are going to be discussed highlighting its hemodynamic impacts. There is no evidence 
about target hemodynamic parameters during post-cardiac arrest syndrome to maintain 
cerebral perfusion neither about the most effective hemodynamic monitoring system. We 
are presenting preliminary data of our study where we investigate the effect of PiCCO™ 
(Pulse index Continous Cardiac Output) monitoring on the outcome in this patient group.
Keywords: post-cardiac arrest syndrome, post-cardiac arrest brain injury, post-resuscitation 
therapy, targeted temperature management, hemodynamic parameters
1. Introduction
Sudden cardiac arrest is one of the leading causes of death in Europe [1]. The outcome is still 
very poor: the hospital discharge varies between 7 and 10% after out-of-hospital cardiac arrest 
(OHCA) and it is approximately 25% after in-hospital cardiac arrest (IHCA) [1]. The chain of 
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survival describes links that lead to a successful resuscitation [2]. The fourth element covers 
proper post-resuscitation care to restore quality of life. It is well known that the management 
of post-resuscitation cardiac arrest syndrome affects outcome and it is an important part of 
the resuscitation process. Pointing out the growing importance of post-resuscitation therapy, 
the European Resuscitation Council (ERC) introduced a separate chapter about post-resusci-
tation care in the 2015 guidelines [3]. One of the key elements to improve survival rate after 
sudden cardiac arrest may be the enhancement of post-resuscitation therapy.
The post-cardiac arrest brain injury remains the main cause of mortality in the post-cardiac 
arrest period, being as high as 68% after OHCA and 25% after IHCA [4]. These data show that 
one of our leading goals during post-resuscitation therapy is to prevent secondary brain dam-
age and guide a proper neuroprotective therapy.
We are going to point out the importance and process of recent neuroprotective strategies in 
this chapter. The role of normoxia, normocapnia, normoglycemia, seizure control, sedation 
and pharmacotherapy will be discussed in brief and we will work out in more details the 
place of control of hemodynamic parameters and targeted temperature management (TTM) 
in post-cardiac arrest condition.
2. Post-cardiac arrest syndrome
The post-resuscitation disease, later called post-cardiac arrest syndrome (PCAS) was first 
described in 1972 by Vladimir Negovsky as the unnatural pathophysiological state created by 
successful cardiopulmonary resuscitation (CPR) once resumption of spontaneous circulation 
has been achieved after whole body ischemia [5].
Post-cardiac arrest syndrome is the unique and complex combination of pathophysiological 
processes, including post-cardiac arrest brain injury, post-cardiac arrest myocardial dysfunc-
tion, systemic ischemia-reperfusion response and the unresolved pathological process caus-
ing cardiac arrest [6]. The contribution of each of these components in an individual patient 
depends on several factors including comorbidities, duration of the ischemic insult and the 
cause of cardiac arrest itself.
2.1. Systemic ischemia-reperfusion response
The pathophysiology of PCAS is very complex and contains processes that are still not 
completely understood. It is dominated by ischemia and reperfusion followed by systemic 
inflammatory response syndrome (SIRS). The reduced oxygen supply during ischemia or 
the so-called “no-flow phase” brings a decrease in adenosine-triphosphate synthesis and 
leads to cell membrane depolarization and opens the voltage-dependent calcium channels. 
Intracytoplasmic calcium level increases as a consequence that is responsible for cell dam-
age. During reperfusion or the “low-flow phase”, blood flow restores but oxygen radical 
species are formed. The hydroxyl radical is cytotoxic and causes cell death [7]. The plasma 
of patients after OHCA was analyzed and an acute pro-oxidant state within the cells was 
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showed [8]. Cytokine production, activation of complements and expression of leukocyte 
adhesion molecules stimulate the activation of polymorphonuclear neutrophils and lead to 
systemic inflammation and multiorgan failure. Inflammatory response syndrome is associ-
ated with changes of hemostasis effecting secondary damage in endothelium that is followed 
by thrombus formation and increased capillary permeability [9]. It is important to point out 
that the worsening of visceral lesions occurs during reperfusion and is extended over the first 
hours, explaining the potential efficacy of delayed TTM. The clinical manifestation of PCAS-
induced inflammatory response reaction shows a lot of similarities with sepsis [9]. The clinical 
picture is dominated by hemodynamic instability in the first hours and days. It leads to organ 
hypoperfusion if untreated and a consecutive multiorgan failure. The hypoperfusion of brain, 
caused by these hemodynamic changes, may lead to secondary brain damage and worse neu-
rological outcome in this patient group.
2.2. Post-cardiac arrest brain injury
The anoxic-ischemic neurological damages remain the leading cause of death occurring in 
patients resuscitated from cardiac arrest [4]. Its clinical manifestation is very widespread: 
coma, seizures, myoclonus, varying degrees of neurocognitive dysfunction and brain death 
may occur [10].
The neurological damage is initiated during “no-flow phase”, but is accelerated during the 
“low-flow period”. The triggers of brain injury after cardiac arrest and a successful resuscita-
tion are: excitotoxicity, disrupted calcium homeostasis, formation of free radicals, activation 
of protease cascades and apoptosis signaling pathways [11, 12]. Most of these pathways acti-
vate over hours to days after the return of spontaneous circulation (ROSC). If cardiac arrest 
is prolonged, failure of microcirculatory reperfusion may appear despite adequate cerebral 
perfusion pressure (CPP) leading to micro-infarctions. On the other hand, in the first min-
utes immediately after ROSC, a macroscopic hyperemia may occur that is caused by elevated 
CPP and impaired autoregulation [13]. As a consequence brain edema and reperfusion injury 
will exacerbate. Mullner et al. showed that a higher mean arterial pressure (MAP) did not 
improve the neurological outcome in the first 5 minutes after ROSC but if they were kept at 
a higher MAP in the first 2 hours after ROSC, the neurological outcome improved [14]. There 
are growing data to show that overload of oxygen during the initial phase after ROSC may 
be also harmful and can exacerbate cerebral damage through mitochondrial injury and free 
radical production [15].
Secondary brain injury may be evoked by a number of insults caused mainly by inappropriate 
post-cardiac arrest treatment in the first hours and days after cardiac arrest: hypo/hyperoxia, 
hypo/hypercapnia, hypotension, hypo/hyperglycemia, pyrexia, impaired cerebral autoregu-
lation and brain edema.
One of the consequences of the primary brain damage is the impairment in cerebral autoregu-
lation, however human data are limited [13]. It results that the cerebral perfusion varies with 
CPP in the acute and subacute phase of the disease. Experimental and clinical studies show 
that cerebral blood flow (CBF) and metabolic rate of cerebral oxygen consumption is decreased 
in the first 24–48 hours after ROSC due to increased cerebral vascular resistance [16].
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Specific brain regions appear to be most commonly affected with events causing poor sys-
temic circulation [17]. These regions are insulted because they lie in watershed vascular areas 
or their neurons are located at areas with a higher metabolic rate and oxygen/glucose demand 
more vulnerable to ischemia.
The neurological syndromes that occur in cardiac arrest survivors can be partially explained 
by the focal areas of brain injury [17]. The CA1 pyramidal neurons of the hippocampus are 
commonly damaged with prolonged ischemia, resulting impairment in memory function-
ing. Cerebellar Purkinje cell injury may result in ataxia, commonly manifesting as a gait dis-
turbance from axial instability. Other commonly affected neurons include thalamic reticular 
neurons, the medium-sized striatal neurons and the pyramidal neurons in the layers 3, 5 and 
6 of neocortex. With more prolonged periods of ischemia, arterial border zone regions can be 
appreciated macroscopically on neuroimaging. Patients with prolonged period of hypoxia 
followed by a global ischemic event appears to be susceptible to preferential injury to the 
subcortical white matter, in what appears to be a primary myelinolytic process. It is postu-
lated that injury occurs preferentially in the subcortical matter in situations in which there is 
a significant period of alveolar hypoventilation, progressive acidosis and severe metabolic 
disturbances in the peri-arrest period.
2.3. Post-cardiac arrest myocardial dysfunction
Post-cardiac arrest myocardial dysfunction also contributes to the low survival rate after 
OHCA and IHCA [4]. However, this phenomenon is responsive to therapy and is reversible. 
Heart rate and blood pressure may be extremely variable immediately after ROSC caused by 
the transient increase in serum catecholamine concentration of endogenous and exogenous 
origin. When post-cardiac arrest myocardial dysfunction occurs, it can be detected within min-
utes of ROSC by appropriate monitoring. During the period with significant dysfunction, coro-
nary blood flow is not reduced, indicating a true stunning phenomenon rather than permanent 
injury or infarction. This global dysfunction is transient and full recovery can occur, usually 
between 24 and 48 hours after the cardiac arrest. The responsiveness of post-cardiac arrest 
global myocardial dysfunction to inotropic drugs is well documented in animal studies [18]. In 
swines, dobutamine infusions dramatically improve systolic (left ventricular ejection fraction) 
and diastolic (isovolumetric relaxation of left ventricle) dysfunction after cardiac arrest [19].
2.4. Persistent precipitating pathology
The pathophysiology of post-cardiac arrest syndrome is commonly complicated by persisting 
acute pathology that caused or contributed to the cardiac arrest itself. On the other hand dif-
ferential diagnosis and management of the precipitating pathology can be made more diffi-
cult by the symptoms and pathophysiologic changes caused by post-cardiac arrest syndrome. 
Some of the most frequent conditions leading to cardiac arrest are the followings: acute coro-
nary syndrome, acute aortic syndromes, pulmonary embolism, pulmonary diseases (COPD, 
asthma bronchiale, pneumothorax), hypovolemia due to hemorrhage or dehydration, sepsis, 
central nervous system diseases and various toxidromes. The potential treatments are inter-
ventions specific for each disease guided by the patient’s condition.
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3. Tools of neuroprotection in post-resuscitation care
3.1. Normoxia and normocapnia
Arterial oxygen could be a modifiable component of patient care after cardiac arrest in order 
to deliver better neurological outcomes.
In the search for modifiable ROSC factors, the role of supplemental oxygen, which is often admin-
istered in high concentrations to patients after cardiac arrest, has come into controversy. Early 
oxygen administration can influence oxidative metabolism, respiratory markers, vasoconstric-
tive status and blood flow, and may thus be an important predictor of outcome [20]. Although 
it is intuitive that insufficient oxygen delivery can exacerbate cerebral anoxia, excessive oxy-
gen delivery can also be harmful by increasing the amount of oxygen free radicals and subse-
quent reperfusion injury. Pure oxygen therapy after cardiac arrest has previously been shown to 
worsen neurological outcome in animal models and exposure to hypocapnia and hypercapnia 
after ROSC has been associated with poor neurological function at hospital discharge [20].
Oxygen creates a paradox when delivered to the damaged brain. If there is too little oxygen 
then potential anoxic injury may occur, while too much oxygen may increase the production 
of oxygen free radicals, leading to cellular injury and apoptosis [21].
In clinically relevant experimental models of cardiac arrest, hyperoxia has been shown to 
worsen the severity of oxidative stress, causing a greater loss of pyruvate dehydrogenase com-
plex, impairment of oxidative energy metabolism and higher oxidation of brain lipids, cul-
minating in more severe brain histopathologic changes and worse neurological deficits [21].
Kilgannon et al. reported data from adult intensive care units (ICU) of 120 US hospitals incor-
porated in a large administrative database named “Project IMPACT” and it included 6326 
patients divided into three groups (hyperoxia, normoxia and hypoxia) according to the first 
partial pressure of oxygen in arterial blood (PaO
2
) obtained within 24 hours following ICU 
arrival [22]. Arterial hyperoxia and hypoxia were defined as a PaO
2
 higher than 300 mmHg 
and a PaO
2
 lower than 60 mmHg, respectively. The authors found that in-hospital mortality 
was significantly higher in the hyperoxia group as compared with both the normoxia and the 
hypoxia group (63 vs. 45 and 57%, respectively).
In addition, among hospital survivors, patients with hyperoxia had a significantly lower like-
lihood of independent functional status at hospital discharge as compared with patients with 
normoxia (29 vs. 38%, respectively).
A secondary analysis showed a dose-dependent association between supranormal PaO
2
 and 
risk of in-hospital death [23]. In particular, 25 mmHg increase in PaO
2
 was associated with 6% 
increase in relative risk of death. Given that the median post-resuscitation PaO
2
 in this sample 
was 231 mmHg, it appears that a high proportion of adult patients resuscitated from cardiac 
arrest have exposure to supranormal oxygen tension. Considering the linear increase in risk 
of death associated with PaO
2
, these results suggest a need for clinical trials of a controlled 
oxygen therapy after resuscitation from cardiac arrest.
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The ERC guidelines for post-resuscitation care recommend the avoidance of unnecessary 
arterial hyperoxia and a controlled reoxygenation strategy targeting an arterial oxygen satu-
ration of 94–96% [3].
Carbon-dioxide (CO
2
) may have neuroprotective properties, as it is thought that mild increase 
in its level improves cerebral perfusion and it has anticonvulsant, anti-inflammatory and anti-
oxidants properties [24]. On the other hand, its decrease has been associated with neuronal 
injury in animal models and after traumatic brain injury.
Schneider et al. published an observational cohort study to observe the relationship between 
arterial CO
2
 partial pressure (PaCO
2
) and outcome in 16,542 patients admitted to the ICU 
after cardiac arrest [24]. This study was the first to report the relationship between PaCO
2
 and 
mortality and an alternative marker of likely neurological outcome.
Within 24 hours of admission, about one in five patients had at least one episode of hyper-
capnia. Such abnormal values most often occurred within the first 2 hours of ICU admission 
and that hypercapnia may have been associated with non-ventricular fibrillation (VF) car-
diac arrest and underlying respiratory disease. Compared with normocapnia, hypocapnia 
was associated with a greater risk of death and a lower likelihood of being discharged home 
among survivors.
On the other hand, hypercapnia was associated with similar mortality or outcome rates to 
normocapnia but with a higher chance of being discharged home among survivors.
Cerebral autoregulation is impaired after ROSC, but cerebrovascular reactivity to CO
2
 is pre-
served. A decrease in PaCO
2
 determines cerebral vasoconstriction with a consequent reduc-
tion of cerebral blood flow (CBF) whereas the opposite occurs when PaCO
2
 is increased. There 
is evidence that CBF could be decreased in the post-resuscitation phase due to an imbal-
ance between local vasodilators and vasoconstrictors but CO
2
-mediated vasodilatation might 
reverse these abnormalities.
The ERC guidelines suggest adjusting ventilation to achieve normocapnia and monitoring the 
ETCO
2
 (end tidal carbon dioxide level) and arterial blood gas values during post-resuscitation 
therapy [3].
3.2. Glucose control
Any stressful systemic injury, such as cardiac arrest, evokes a complex response involv-
ing glucoregulatory hormones such as catecholamines, glucagon and glucocorticoids. The 
increase of these hormones may result in glucose intolerance and hyperglycemia, as they can 
mobilize glucose and other energy substrates from storage pools. Glucose metabolism via 
anaerobic glycolysis is the only brain energy pathway that can sustain energy metabolism for 
any significant period of time (minutes) during an ischemic episode.
Unfortunately, it is common following CPR that the transport of glucose to brain tissues may 
become inadequate to satisfy cerebral metabolism [25]. Consequently, when cerebral perfu-
sion is compromised, moderate hyperglycemia may facilitate glucose transport through the 
elevated blood glucose diffusion gradient that maximizes cellular glucose uptake.
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On one hand, there are various studies that have shown that high blood glucose levels after 
ROSC are associated with increased mortality and poor neurological outcome for patients 
who experience OHCA. For IHCA patients, Beiser et al. reported that for patients without dia-
betes mellitus, both hypoglycemia and hyperglycemia were associated with decreased sur-
vival odds. However, for patients with diabetes mellitus, there was little association between 
blood glucose level and survival, except with extreme hyperglycemia [26].
On the other hand, there are several studies that have found out that normalization of blood 
glucose levels in critically ill patients with brain injury may be associated with greater risk 
of critical reductions in brain glucose levels and energy crises [27]. Therefore, acute stress 
hyperglycemia noted during the early post-ROSC phase might be a physiologic, rather than a 
pathologic response and attempts at interfering with this complex adaptive response may be 
harmful rather than protective.
It is proven that hypoglycemia needs to be avoided in critically ill patients. In a study by Arabi 
et al., mortality in patients with hypoglycemia was multipled compared to patients with con-
ventional therapy [28]. Unrecognized episodes of hypoglycaemia are more harmful than the 
benefit of strict normoglycemia, especially in patients with brain damage [29].
The American Heart Association (AHA) guidelines do not recommend a target blood glu-
cose range for post-ROSC patients [30]. The ERC guidelines suggest that blood glucose level 
should be maintained below 180 mg/dl (10 mmol/L) in these patients and that hypoglycemia 
should be strictly avoided [3].
3.3. Seizures control
Many of patients who remain comatose after successful resuscitation, will suffer from sei-
zures. The appearance of seizures may be variable, from single focal onset through myoclo-
nus to generalized tonic-clonic fit.
Acute post-hypoxic myoclonus (PHM) occurs in about 18–25% of these patients, typically 
within the first 24 hours after CPR [31]. Commonly, the myoclonus appears days or weeks 
after the hypoxic episode when consciousness is regained. Myoclonus is a hyperkinetic 
movement disorder characterized as a sudden, jerky, shock-like movement. It can involve 
different body parts individually (focal), contiguously (segmental) or asynchronously 
(multifocal). When repetitive, the jerks may be regular or irregular, sometimes mimicking 
tremor.
There are several EEG findings in acute PHM: burst suppression (56%), spike-wave activity 
(37%), myoclonic status epilepticus (31%), diffuse slow background and waves (21%) and 
alpha coma (7%). These severe diffuse EEG abnormalities are consistent with marked diffuse 
cerebral dysfunction.
The exact neuronal damage and pathophysiology that gives origin to acute PHM is not clear. 
[32] Treatment is indeed challenging and no published guidelines exist as the hypoxic injury 
may lead to mixed and varying clinical findings of this myoclonus. Moreover, a drug treat-
ment for one type may not work well in another or may even induce worsening [33].
Strategies of Neuroprotection after Successful Resuscitation
http://dx.doi.org/10.5772/intechopen.70593
167
3.4. Sedation
Sedative agents play a vital role in the management of patients with an acute brain damage. 
However, there is no evidence to support the defined duration of sedation neither the agent 
that should be used after cardiac arrest. Sedation acts to protect the brain against the exten-
sion of primary acute brain injury and secondary cerebral insults [34]. It has always been 
used in association with cooling methods, since the first non-randomized trials investigating 
targeted temperature management or therapeutic hypothermia (TH) effects on outcome. In 
this setting sedatives were often co-administered with muscle relaxants.
The main goals to use sedation during targeted temperature management are the reduction 
of oxygen consumption, control of shivering, the reduction of agitation and ventilator dys-
synchrony, which may be detrimental for neurological recovery [34]. Clinically detectable 
shivering can increase systemic metabolic rate with 24–160% above baseline resting energy 
expenditure and increase inflammatory markers. The use of neuromuscular blocking agents 
to avoid shivering is controversial and we think it should be the agent of an ultimate case 
because it may mask seizures and its prolonged use (more than 1 day) may lead to muscle 
weakness, prolonged ventilation and ICU stay.
There are no data about the influence of outcome of sedatives used after cardiac arrest. A 
combination of hypnotics and opioids is used in the most of cases [35]. Short-acting drugs are 
preferred, for example, remifentanil, alfentanil and propofol.
3.5. Pharmacologic strategies
There is still lack of proved pharmacological interventions providing neuroprotection for 
patients after successful resuscitation. However, there are some promising drugs that may 
have some beneficial effect on neurological recovery in this patient group. Most of these 
agents have been studied in experimental research and only a few clinical data are achievable.
Xenon is one of the most commonly investigated pharmacologic treatments in post-resus-
citation therapy. Pre-clinical studies have shown that it can prevent the development of 
ischemic-reperfusion brain injury [36]. A randomized single blind trial investigated the cere-
broprotective effect of xenon in 110 comatose patients after OHCA [37]. One half of patients 
received xenon combined with therapeutic hypothermia and the other half was treated only 
with hypothermic therapy. They did not find any difference in survival and neurologic out-
come after 6 months but there was less white matter damage controlled with magnetic reso-
nance imaging (MRI) in the xenon-treated group. On the basis of these findings the efficacy of 
xenon must be investigated in further clinical trials at this patient group. Also we need to point 
out its disadvantages: it is still quite expensive and its storage needs special circumstances.
The impact of early high-dose erythropoietin was also investigated in patients after OHCA in 
a single blind randomized trial but neither mortality, neither Cerebral Performance Category 
(CPC) scale improved after this treatment, only rate of thrombotic complications increased [38].
Rosuvastatin was shown to improve survival, myocardial function and neurologic recovery in 
a rat model after successful resuscitation [39]. A combination of three drugs (lovastatin, mino-
cycline and lamotrigine) was also studied in a mouse model after brain ischemia provoked by 
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artery carotid occlusion [40]. As a result a decreased neurological deficit was reached suggest-
ing a potential beneficial effect of this treatment in post-cardiac arrest therapy.
One of the promising, easily achievable and affordable drugs that may have potential benefit 
in neuroprotection after cardiac arrest is thiamine. It is a type of B vitamins that is essential for 
the proper functioning of nervous system. It modulates the activity of pyruvate dehydroge-
nase that is a main enzyme in Krebs cycle. It has been shown that mitochondrial dysfunction 
and impaired aerobic metabolism may be a cause of cerebral damage after cardiac arrest [41]. 
This led to the idea to investigate the effect of thiamine in mice after successful resuscita-
tion [42]. Mice treated with thiamine after cardiac arrest had a better 10-day survival and 
improved neurological outcome than control individuals. The histology also showed an ame-
liorated brain injury after thiamine treatment. The investigators also checked the activity of 
pyruvate dehydrogenase in human blood in patients after successful resuscitation and found 
that it was significantly lowered compared to control healthy volunteers. We think thiamine 
may be a pharmacological pathway in treating post-cardiac arrest brain injury but its clinical 
effect and proper dosage need to be investigated in clinical trials.
3.6. Targeted temperature management
3.6.1. Principles and guidelines
Two trials published by the New England Journal of Medicine in 2002, involving patients who 
remained unconscious after resuscitation from cardiac arrest, compared therapeutic hypo-
thermia (32–34°C for 12–24 hours) with standard treatment [43, 44]. These trials showed a sig-
nificant improvement in neurologic function and survival with therapeutic hypothermia. This 
treatment method was incorporated into the resuscitation guidelines in 2005. For more than a 
decade, mild-induced hypothermia (32–34°C) was the standard of care for patients remaining 
comatose after resuscitation from OHCA with an initial shockable rhythm, and this has been 
extrapolated to survivors with initially non-shockable rhythms and to patients with IHCA.
Traditionally, therapeutic hypothermia (TH) refers to deliberate reduction of the core body 
temperature to a range of 32–34°C in patients who do not regain consciousness after ROSC.
Since the 2015 ERC guidelines, term targeted temperature management (TTM) is suggested 
to use instead of therapeutic hypothermia and the new recommendation is to keep patients’ 
core temperature between 32 and 36°C [3]. However, this expression is not always unique and 
many use phrase therapeutic hypothermia for goal temperature 32–34°C and term TTM for 
goal temperature 36°C.
There are still several unanswered questions regarding targeted temperature management 
after cardiac arrest. We still do not exactly know which patients benefit from lower and which 
from a higher level of temperature. Only the detrimental effect of fever is proven of the effects 
of temperature in post-cardiac arrest syndrome. Further questions are when exactly to start 
cooling and how long to keep cooling, which still need more clinical trials to be answered.
The 2016 guidelines of American Academy of Neurology (AAN) on reducing brain injury fol-
lowing cardiac arrest try to give a more precise direction how to handle temperature manage-
ment in this patient group [45].
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Because patients with initial rhythm of ventricular fibrillation/ventricular tachycardia (VF/
VT) or pulseless electrical activity (PEA)/asystole differ in causes of cardiac arrest and out-
come, the guideline deals separately with these patient groups. It recommends the use of 
therapeutic hypothermia (32–34°C for 24 hours) if the initial rhythm was VF/VT and patients 
remain comatose after successful resuscitation. It also says that for patients with an initial 
rhythm of VF/VT or PEA/asystole TTM (36°C for 24 hours followed by 8 hours of rewarming 
to 37°C and temperature maintenance below 37.5°C until 72 hours) is likely as effective as TH 
and may be a good alternative. If the initial rhythm is PEA/asystole, than the use of TH pos-
sibly improves outcome over non-hypothermia treatment.
In 2013 a trial to investigate the benefits and harms of two targeted temperature regimens was 
conducted, called the Targeted Temperature Management (TTM) trial [46].
In the TTM trial, 950 all-rhythm OHCA patients from 36 ICUs in Europe and Australia were 
randomized for 36 hours of temperature control (comprising 28 hours at the target tem-
perature followed by slow rewarm) at either 33°C or 36°C. Temperature was managed with 
intravascular or surface cooling devices for 36 hours, while the patients were sedated and 
mechanically ventilated. TTM at 33°C was associated with decreased heart rate, elevated 
serum lactate level, the need for increased vasopressor support and a higher extended cardio-
vascular SOFA score compared with TTM at 36°C. However, it is important to point out the 
higher proportion of bystander witnessed cardiac arrest (90%) and of bystander CPR (73%). 
Moreover, the time to start basic life support (BLS) was shorter in both groups, among 1 min-
ute. These facts by themselves would provide an improvement in the outcome of patients 
regardless the hypothermia. Nevertheless, the median time of ROSC was 25 minutes in both 
groups.
The TTM trial has also been criticized because the temperature was tightly controlled and 
it took a short time to reach 33°C, but also because the whole trial cohort was less ill than 
in previous trials. It should be taken into account that the previous studies were performed 
several years ago, and that during the last decade the intensive care therapy has improved a 
lot itself [47].
It is also a very important fact that in TTM trial there was no fever during the therapy. When 
comparing the TTM trial and the previous trial temperature results, we can appreciate that 
the temperature after re-warming was lower in the TTM trial [43, 44, 46].
Kaneko et al. conducted an observational study between January 2005 and March 2013 called 
the J-Pulse-Hypo Japanese prospective cohort. The objective of the study was to identify sub-
groups of patients who might be suitable candidates for lower targeted temperature during 
TTM after ROSC [48].
Participants were divided into lower (32–33.5°C) or moderate (34–35°C) temperature groups. 
In this study a favorable primary outcome was defined as CPC (Cerebral Performance 
Category) 1–2 on day 30. The subgroups of patients were divided and analyzed in the follow-
ing way: age ≤60 vs. >60 years and resuscitation interval of ≤30 vs. >30 minutes.
The results demonstrated that the lower temperature group significantly improved the pro-
portion of patients with favorable neurological outcomes in the subgroup of patients with a 
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resuscitation interval of ≤30 minutes. There were some differences between this study and 
the TTM Trial, including shorter time to reach the targeted temperature (180 minutes), longer 
time at the targeted temperature (34 hours), and longer re-warming period (3 days).
When to start cooling is also an interesting and still unanswered question regarding TTM. It 
was shown in preclinical studies that initiating cooling as soon as possible after resuscita-
tion improves neurologic outcome [49]. Clinical studies investigating the beneficial effects of 
cooling initiated in pre-hospital setting did not show positive outcome. A Cochrane review 
studied 7 trials (2369 patients) investigating the effect of pre-hospital cooling on survival, 
cerebral injury, side effects, quality of life and length of hospital stay [50]. There was no differ-
ence in survival between pre-hospital and intra-hospital cooling groups, neither in neurologic 
outcome. The rate of re-arrests was higher among patients who received pre-hospital cooling 
in four of the investigated trials.
The guidelines of AAN do not suggest the use of pre-hospital cooling while it is ineffective 
in improving neurological outcome and survival [45]. One of the explanations for this phe-
nomenon may be the fact, which has been already mentioned, that there are some complex 
mechanisms leading to post-cardiac arrest brain injury appearing some hours after ROSC. On 
the other hand high volumes of cold infusions are used to initiate TTM during pre-hospital 
cooling leading to pulmonary edema and complications causing more harm than benefit. We 
also need to mention the heterogeneity of studied cooling methods in pre-hospital setting. To 
prove its efficacy or inefficiency further studies are needed.
3.6.2. Beneficial effects in post-cardiac arrest syndrome
Hypothermia provides significant cardiac and neurological protective effects through differ-
ent pathways. Hypothermic mechanisms providing myocardial protection include improved 
energy production during ischemia, increased calcium sensitivity of myocytes, regulation of 
mitochondrial oxidative phosphorylation and preserved myocardial vascular autoregulation. 
All of these protective mechanisms would result in increased myocardial contractility.
After a post-anoxic injury, hypothermia may also protect cerebral function through decreas-
ing apoptosis, reducing the release of excitatory (glutamate and dopamine) neurotransmitters, 
attenuating the reactive oxygen species production, preserving the blood-brain barrier, provid-
ing protection of cerebral microcirculation and decreasing intracranial pressure. Hypothermia 
decreases the cerebral metabolic rate of oxygen by about 6% for each 1°C reduction in core 
temperature and this may reduce the release of excitatory amino acids and free radicals.
Shivering will increase metabolic and heat production, thus reducing cooling rates. The 
occurrence of shivering in cardiac arrest survivors who undergo mild induced hypothermia 
is associated with a good neurological outcome. Occurrence of shivering was similar at a tar-
get temperature of 33 and 36°C.
Mild induced hypothermia increases systemic vascular resistance and causes arrhythmias 
(usually bradycardia). However, the bradycardia caused by mild induced hypothermia may 
be beneficial: it reduces diastolic dysfunction and its occurrence has been associated with 
good neurological outcome.
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3.6.3. Side effects
Therapeutic hypothermia is an effective tool in neuroprotection after cardiac arrest, how-
ever it may cause several side effects that need to be monitored and declined during its use. 
Polyuria and electrolyte abnormalities such as hypophosphatemia, hypokalemia, hypomag-
nesemia and hypocalcemia may appear.
Insulin sensitivity and insulin secretion are decreased, that lead to hyperglycemia. Moreover, 
coagulation system can get impaired and bleeding risk is increased.
Hypothermia can impair immune system and extend infection rates. It is associated with an 
increased incidence of pneumonia, although the use of prophylactic antibiotics may prevent 
it to emerge.
The clearance of sedative drugs and neuromuscular blockers is reduced by up to 30% at a 
core temperature of 34°C. Clearance of sedative and other drugs will be closer to normal at a 
temperature of 37°C.
3.6.4. Practice of cooling
Whenever the indication is established the hypothermic treatment should be started as soon 
as possible. The trial performed in 2002 had the induction within 6–26 hours, with a median 
of 8 hours [43].
Hypothermic treatment and TTM has three phases such as induction of cooling, maintenance 
and rewarming.
Cooling may be delivered via external, internal and combined cooling methods. External 
cooling is carried out by traditional icepacks placed on the groin, axilla and sides of neck; 
surface temperature changer devices with thermo-feedback function such as blankets or self-
adhesive plastic fluid-containers or cooling helmets over the head of the patient.
Internal cooling means intrabody cooling as intravascular, intrabladder or intragastrical 
method. It may be delivered via infusion of 30 ml/kg of 4°C saline, which decreases core 
temperature by 1.5°C. Intravascular cooling enables more precise control than external meth-
ods. The most precise temperature control with the fastest induction, reaction to temperature 
changes and rewarming is achievable via endovascular heat-exchange catheter. This latter is 
the most expensive method on the field.
3.6.5. Practice of TTM and post-cardiac arrest therapy in Semmelweis University Heart and 
Vascular Center
• Protocolisation: our cardiac ICU has a prospective protocol of care to anticipate, monitor, 
and treat each of the impaired organ functions by optimizing systemic perfusion, restor-
ing metabolic homeostasis and support organ system function to increase the likelihood of 
survival with potentially good neurological outcome.
• Technical background: our cardiac ICU has 11 monitored beds, with central monitoring sys-
tem as well. Seven invasive mechanical ventilators, two non-invasive mechanical  ventilators 
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and four intraaortic balloon pumps are available. For patients who need mechanical cir-
culatory support extracorporeal membrane oxygenator (ECMO)/ventricular assist device 
(VAD) background is available by the cardiac surgeons and cardiac surgical ICU.
• TTM target temperature: 33°C. The target time to achieve target temperature is usually 
3–6 hours using thermo-feedback blanket device (Figure 1) and 1–2 hours using intravascu-
lar cooling catheters. Latter is rarely used due to the price of the catheter. The maintenance 
duration of target temperature is 24 hours. Rewarming duration is set to 0.25°C/hour that 
means approximately 16 hours. Invasive hemodynamic monitoring during TTM is also 
used but only upon the attending physician’s preference and the equipment availability.
• Intubation and mechanical ventilation is always obligatory during TTM since sedation and 
if needed neuromuscular blockade is also used in these patients. Midazolam is the choice 
of sedation if the patient is hemodynamically unstable and propofol, if the patient is stable. 
Opioids are administered to decrease the cerebral metabolic rate additionally.
• Tight monitoring of invasive blood pressure, rhythm, ECG morphology, diuresis, core tem-
perature and hemodynamic variables is obligatory.
• Prevention is also started at admission: the post-cardiac arrest patients with circulatory 
impairment are at higher risk of decubitus, stress ulcer and infections.
• Sampling from trachea, pharynx, nose, groins for cultures are done at admission and em-
piric intravenous antibiotic therapy is initiated. Infection risk is 7–17% by the literature, but 
no significant effect on mortality was shown.
• We plan to establish a continuous EEG monitoring during sedation and TTM but it is avail-
able only in limited fashion at the moment.
3.7. Cerebral perfusion
Patients with post-cardiac arrest syndrome experience on-going oxidant damage, profound 
systemic inflammation with vasodilation, myocardial stunning and adrenal axis suppression, 
which commonly result in major hemodynamic instability. Targeted temperature manage-
ment with a lower core body temperature affects circulatory variables also negatively. As we 
previously mentioned the injured brain commonly has a dysfunctional autoregulation. This 
leads to the fact that blood pressure alterations in the post-cardiac arrest period may influence 
on-going cerebral injury and eventual neurologic outcome [51]. With disruption of normal 
cerebrovascular autoregulation, CBF may become directly related to cerebral perfusion pres-
sure, which is dependent on MAP.
Hypotension may lead to persistent tissue hypoperfusion after ROSC, which may produce 
secondary cellular injury after the initial insult.
Kilgannon et al. studied the time-weighted average mean arterial pressure (TWA-MAP) for 
the first 6 hours after ROSC [51]. It was found that arterial hypotension was common while rel-
atively fewer patients had an intrinsic hypertensive surge. It was determined that TWA-MAP 
was associated with neurologic outcome. This association appears to be driven by the strong 
association between hypotension and poor neurologic outcome, as opposed to an association 
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between intrinsic hypertension and better neurologic outcome. In the analysis, there was a 
threshold effect with a TWA-MAP greater than 70 mmHg having the greatest association with 
good neurologic function, and they did not find higher MAP thresholds to be associated with 
favorable outcome.
The frequency and significance of post-ROSC arterial hypotension among cardiac arrest victims 
was measured at the time of ICU admission in a large, multicenter cohort study performed by 
Trzeciak et al. [52]. It was found that 47% of patients who survive cardiac arrest have post-ROSC 
hypotension, and two-thirds of these patients do not survive to hospital discharge. The presence 
of post-ROSC hypotension at the time of ICU admission is associated with an approximate two-
fold risk of in-hospital mortality. It was identified that the post-ROSC condition is characterized 
by patchy microcirculatory cerebral hypoperfusion, and arterial pressure in the post-cardiac 
arrest period is a major determinant of the degree of cerebral perfusion impairment.
In spite of the studies that have tried to determine the appropriate blood pressure target after 
ROSC for a better neurological outcome, the results have not been conclusive. A recent study 
showed inverse effect between arterial pressure and survival [53]. In the absence of definitive 
data, the ERC guidelines recommend a target blood pressure that secures a satisfactory urine 
output (1 ml/kg/h) and a decreasing/normalizing lactate level taking into consideration the 
patient’s normal blood pressure [3].
Figure 1. Thermo-feedback device used for external cooling in our practice.
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As a conclusion we can state that there are no clear data about the target blood pressure in 
post-cardiac arrest patients neither in shock patients [54]. There is lack of studies investigating 
the optimal target blood pressure in cardiogenic shock. However, it is showed that a target 
MAP of 65 mmHg may be satisfactory in septic shock patients, we need to point out that it is 
associated with a higher risk of acute kidney injury if the patient has a history of hypertension 
[55]. The main message of these findings is that the target blood pressure should be individu-
alized to secure a proper perfusion of organs and an adequate perfusion of brain to prevent 
further secondary cerebral damage.
3.8. Hemodynamic monitoring during post-cardiac arrest syndrome and the 
hemodynamic effects of therapeutic hypothermia: a case control study (preliminary data)
We think that an expanded hemodynamic monitoring may be a more precise and useful tool 
to guide the hemodynamic management of post-cardiac arrest patients than observing only 
blood pressure. As we mentioned previously, there are several components leading to hemo-
dynamic instability in this patient group and we need to mention also the complexity of the 
precipitating pathology causing cardiac arrest. To monitor cardiac output and its components 
(preload, afterload and contractility) gives a more synthetic picture about the condition of the 
patient’s circulation and consecutive organ perfusion.
The most ideal method should be the least invasive providing the most information about the 
patient’s circulatory condition with a simple usability. Echocardiography is a method that 
helps in characterizing the hemodynamic disorders, selecting the most optimal therapeutic 
intervention and assessing the response to it [54]. On the other hand it should be mentioned 
as a limitation that it is not a continuous technique for hemodynamic monitoring and it needs 
a lot of time of practice to reach an adequate level of usage.
Pulmonary artery catheter (PAC) provides important information about hemodynamic vari-
ables and tissue perfusion but it is one of the most invasive tools and there is no evidence 
about its superiority over other monitoring methods [56]. It is not the most useful system in 
determining preload because it measures only static parameters (central venous pressure and 
pulmonary occlusion pressure) instead of dynamic variables. The 2015 European Society of 
Intensive Care Medicine (ESICM) consensus on hemodynamic monitoring does not recom-
mend its routine use in shock only in refractory shock with right ventricular dysfunction [54].
Transpulmonary thermodilution devices like PiCCO™ (Pulse index Contour Cardiac Output) 
are less invasive than PAC and they still provide enough precise information to be used in 
critically ill patients. Its additive advantage is the possibility to measure dynamic variables in 
fluid management. Tagami et al. validated this method in post-cardiac arrest patients even if 
therapeutic hypothermia (32–34°C) was used [57].
Recently developed non-invasive methods using pulse contour analysis and volume clamp 
technique to measure cardiac output should be limited to perioperative use because its value 
during shock, vasopressor therapy or targeted temperature management is questionable [54].
There is no evidence if the use of these methods affects patients’ outcome in critical care not 
even in post-resuscitation therapy. Taking the above mentioned findings altogether we think 
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PiCCO™ monitoring system may be a suitable tool in post-cardiac arrest patients hemody-
namic monitoring. There is still lack of evidence which hemodynamic variables should be 
monitored and which parameters should be targeted.
The aim of our study was to investigate if the use of PiCCO™ monitoring and the PiCCO™-
guided hemodynamic assessment of post-cardiac arrest patients affect the survival, length of 
ventilation, length of ICU stay and the application of catecholamines. We also investigated 
the changes of hemodynamic variables during therapeutic hypothermia and were interested 
in how the most important tool of neuroprotection in post-cardiac arrest syndrome affects 
hemodynamics.
3.8.1. Patients and methods
We enrolled comatose patients after successful resuscitation who received therapeutic hypo-
thermia and were treated in Semmelweis University Heart and Vascular Center between 2008 
January and 2012 July. Inclusion and exclusion criteria are specified in Figure 2. We excluded 
patients who were given hypothermic therapy with physical cooling and ice packs, because 
the target temperature was not reached in most of the cases.
The post-resuscitation therapy and therapeutic hypothermia was initiated as soon as possible 
after the admission following the ERC guideline. The goal temperature was 32–34°C according 
to the even actual protocol (that is the reason we use term “therapeutic hypothermia” instead 
of “targeted temperature management”). The hypothermic treatment contained three phases: 
induction, maintenance and rewarming. The patients received 30 ml/kg cold (4°C) crystalloids in 
Figure 2. Inclusion and exclusion criteria.
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the induction phase and were further cooled with Blanketrol III™ (Cincinatti SubZero) thermo-
feedback device. The same device was used during the maintenance phase. The rewarming was 
a passive process where we tried to keep the 0.25°C/h rewarming speed. The patients’ tempera-
ture was measured with an esophageal thermometer and they were sedated with benzodiaz-
epine and opioids given intravenously. If it was indicated, we performed coronarography and 
percutanous coronary intervention before initiating hypothermia.
Patients were divided into two groups on the basis of what type of hemodynamic monitoring 
has been administered. We monitored by the members of nonPiCCO group oxygen satu-
ration, ECG, invasive arterial blood pressure, central venous pressure, diuresis, blood gas 
parameters and serum lactate level. The patients’ vasopressor, inotrope and fluid therapy was 
guided on the basis of these variables.
The previously mentioned monitoring and interventions were augmented with PiCCO™ 
(Pulsion Medical System) thermodilution device in PiCCO group. We accomplished a mea-
surement at the initiation of hypothermia and performed it every 6 hours in the first 48 hours 
of treatment. The following variables were controlled: cardiac index (CI: l/min/m2), systemic 
vascular resistance index (SVRI: dyn sec/cm5), global end-diastolic volume index (GEDI: l/m2), 
extravascular lung water index (ELWI: ml/kg/m2).
The allocation of patients was directed by the access of the thermodilution device. Mortality, 
circumstances of CPR, length of ventilation and ICU stay and the usage of catecholamine ther-
apy were recorded in both groups and compared. In PiCCO group, the hemodynamic vari-
ables (CI, SVRI, GEDI, ELWI) were controlled at the initiation of hypothermia, in the 12th, 24th 
and 48th hour of hypothermia and after rewarming. The statistical analysis was performed 
with two-tailed t-test and Mann-Whitney test when we compared the two groups. We used 
Wilcoxon test and Bonferroni correction in analyzing the PiCCO measurements. Significance 
of p value was set at <0.05. The Semmelweis University Regional and Institutional Committee 
of Science and Research Ethics accepted our study.
3.8.2. Results
We treated 147 successfully resuscitated patients in Semmelweis University Heart and 
Vascular Center between 2008 January and 2012 July. On the basis of our inclusion and exclu-
sion criteria 40 patients were enrolled into our study: 28 in PiCCO group and 12 in nonPiCCO 
group. There was no significant difference in demographic data and the circumstances of CPR 
between the two groups (Table 1).
The survival (Figure 3), length of ventilation and length of ICU stay were also similar in both 
groups (Table 1). Length of ventilation was 5 ± 3 days in PiCCO and 6 ± 5 days in nonPiCCO 
group, respectively (p = 0.57). The patients in PiCCO group spent 7 ± 4 days at ICU and the 
members of nonPiCCO group 8 ± 5 days (p = 1.00).
In the usage of catecholamines we found that patients in nonPiCCO group received less vaso-
pressors and inotropes than patients in PiCCO group (PiCCO: 71% of patients vs. nonPiCCO: 
58% of patients), however the difference was not significant (Table 2).
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Figure 3. The comparison of survival between PiCCO and nonPiCCO group.
PiCCO (n = 28) nonPiCCO (n = 12) p
Age (years) 62 ± 10 69 ± 8 0.095
Male 82% 67% 0.25
Female 18% 33%
OHCA 64% 46% 0.22
IHCA 36% 54%
Time until ROSC (minutes) 13 ± 6 17 ± 4 0.059
Initial rhythm
VF/pnVT 63% 58% 0.4
PEA/Asy 37% 42%
Bystander CPR
Performed 72% 90% 0.07
Did not performed 18% 10%
Length of mechanical ventilation (days) 7 ± 4 8 ± 5 0.57
Length of ICU stay (days) 5 ± 3 6 ± 5 1
OHCA: out-of-hospital cardiac arrest; IHCA: in-hospital cardiac arrest; ROSC: return of spontaneous circulation; VF: 
ventricular fibrillation; VT: ventricular tachycadria; PEA: pulseless electrical activity.
Table 1. The comparison of demographic data, circumstances of CPR, length of mechanical ventilation and length of ICU 
stay between PiCCO and nonPiCCO groups. Significance of p value was set at <0.05. 
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In the course of the measurement of hemodynamic variables during therapeutic hypothermia 
there was significant difference in cardiac index and systemic vascular resistance index between 
the values in the 12th hour of hypothermia and after rewarming (CI: 1.8 ± 0.5 l/min/m2 vs. 
2.9 ± 0.9 l/min/m2, p < 0.001; SVRI: 3686 ± 1264 dyn sec/cm5 vs. 1627 ± 414 dyn sec/cm5, p < 0.001) 
(Figure 4). Cardiac index decreased in the first 12–24 hours and showed improvement after this 
period. Systemic vascular resistance index changed parallel with cardiac index but the opposite 
way. The changes in ELWI and GEDI did not show significant difference during the examined 
interval.
3.8.3. Discussion
Post-resuscitation therapy as the fourth link of chain of survival is one of the mortality 
determining factors among post-cardiac arrest patients. One of the most important parts of 
Combination of catecholamines PiCCO (n = 28) (%) nonPiCCO (n = 12) (%)
0 29 42
1 36 25
2 21 8
3 14 25
Table 2. The comparison of catecholamine administration between PiCCO and nonPiCCO group.
Figure 4. The changes of hemodynamic variables during therapeutic hypothermia (CI: cardiac index; SVRI: systemic 
vascular resistance index; GEDI: global end-diastolic volume index; ELWI: extravascular lung water index; H: hour).
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 post-resuscitation therapy is the proper attendance of cardiovascular disorders and an ade-
quate guidance of hemodynamic management. The main goal is to secure a satisfactory organ 
perfusion and to prevent secondary brain damage by providing a sufficient cerebral blood 
flow despite the impaired cerebral autoregulation.
As we mentioned previously, there are several components leading to hemodynamic insta-
bility in patients after successful resuscitation [6]. There is pronounced vasodilatation due 
to systemic inflammatory response syndrome (SIRS) following an ischemia-reperfusion epi-
sode. The precipitating pathology itself resulted that cardiac arrest is a cardiovascular disease 
in most of cases. Cardiac stunning may develop after ROSC as a consequence of SIRS.
Targeted temperature management and therapeutic hypothermia may also affect hemody-
namic variables of post-cardiac arrest patients in a negative manner: bradycardia, decrease 
in cardiac output and increase in systemic vascular resistance can evolve [58, 59]. As a conse-
quence of lower temperature primarily during induction phase polyuria may occur resulting 
in hypovolemia [60]. Systolic and diastolic dysfunction was provoked in pigs while they were 
treated with hypothermia [61]. On the other hand these effects may be advantageous in this 
patient group because it has been shown that post-cardiac arrest patients with bradycardia 
had better outcome than patients whose heart rate was higher [62]. The increase of systemic 
vascular resistance is also a beneficial effect and may compensate the vasodilatory conse-
quence of SIRS.
Bernard et al. used PAC as a hemodynamic monitoring in post-cardiac arrest patients and 
found that cardiac index was in tendency lower and systemic vascular resistance index was 
significantly higher in hypothermic group compared to normothermic patients [44]. It was 
also shown that cardiac index was in 66% of patients below 1.5 l/min/m2 in the first 12 hours 
after ROSC in OHCA patients who were treated with therapeutic hypothermia. [63] They also 
used PAC to monitor hemodynamic variables.
As we mentioned it previously, we chose PiCCO™ monitoring system because it is less inva-
sive than PAC and it was earlier validated in PCAS and therapeutic hypothermia [57]. We 
found during our measurements that cardiac index had the lowest value in the 12th hour of 
hypothermic treatment and it was significantly higher after rewarming. Investigating periph-
eral vascular resistance we measured the highest value of SVRI in the 12th hour of therapeutic 
hypothermia and a significantly lower value after rewarming. Our findings are similar to the 
measurements that have been performed with PAC.
On the basis of our results we think that there is a deteriorating hemodynamic instability 
during the first 24 hours after ROSC as a part of post-resuscitation syndrome. We also need to 
point out that treatment with lower temperature may also affect hemodynamic parameters. 
Our opinion is that taking these facts into consideration it is important to use a higher level of 
hemodynamic monitoring in this patient group to guide our hemodynamic therapy mainly if 
the patients are treated with targeted temperature management.
It is a different question if hemodynamic monitoring affects patients’ outcome and mortality. 
There is no evidence which non-invasive, semi-invasive or invasive tool for hemodynamic 
monitoring should be used in critically ill patients. We think the answer is not simple and 
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depends on patient, disease, patient’s condition and the staff’s practical knowledge. There is 
no evidence neither which parameters should we monitor and target during our therapy. To 
get closer to the answer more studies and randomized controlled trials are needed.
We were investigating in our study weather PiCCO™-guided therapy affects outcome in 
patients after successful resuscitation. There was no significant difference in demographic 
data and the circumstances of CPR between the two groups, so they were comparable. There 
was no difference in mortality, neither in the length of ventilation nor ICU stay between the 
groups. We found the same what was previously published in international literature. We 
found that in tendency more vasopressors and inotropes were used during the PiCCO™-
guided therapy. It is very important to use these agents for the shortest time and in the lowest 
dose as possible to avoid side effects. PiCCO™-guided therapy, as it is shown in our study, 
may be a helpful equipment to fulfill this role.
The limitation of our study is the low number of study participants. We are planning to 
expand the investigation and we hope that with the increased number of patients enrolled we 
are getting a clearer result.
3.8.4. Conclusion
As a conclusion of our study, we can say that PiCCO™-guided therapy did not improve 
mortality, length of ventilation and ICU stay among our post-cardiac arrest patients. On the 
other hand we need to point out that it may play a role in conducting the vasoactive and ino-
trope therapy more adequately in this patient group. We proved that the decrease of cardiac 
index and increase of systemic vascular resistance index is observable also with PiCCO™ 
monitoring in the first 24 hours after successful resuscitation, during targeted temperature 
management.
4. Summary
A strong chain of survival can increase the chances of survival and recovery for victims of 
cardiac arrest. We summarized our recent knowledge about neuroprotective strategies after 
successful resuscitation in this chapter, that is, one of the most important parts of post-resus-
citation therapy.
Normoxia, normocapnia, normoglycemia and a proper level of sedation must be maintained 
in order to avoid secondary brain damage. The use of pharmacologic strategies is question-
able but thiamine may be a promising agent in improving neurological outcome. Its efficiency 
needs further clinical investigations.
Targeted temperature management is the most effective tool in our hand today. It has posi-
tive effect in the neurological recovery by decreasing fever, providing myocardial protection, 
slowing the brain metabolism and decreasing the inflammatory response. However, there are 
still many questionable topics in its implementation, like the targeted temperature, method, 
timing, duration of the therapy and the rewarming rate.
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The proper management of hemodynamics in this patient group is also essential to secure 
a satisfactory brain perfusion, but the way of hemodynamic monitoring and the targets of 
hemodynamic variables are also subjects of further investigations. We think that PiCCO™-
guided therapy can be a good direction to tailor vasopressor, inotrope and fluid therapy after 
cardiac arrest and during TTM.
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